A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16

Trial Profile

A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 May 2017

At a glance

  • Drugs Immunoglobulin G (Primary)
  • Indications Agammaglobulinaemia; Immunodeficiency disorders
  • Focus Adverse reactions
  • Sponsors Biotest Pharmaceuticals
  • Most Recent Events

    • 26 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top